Latest Europe News

Battery Age Minerals has wrapped up its 2025 drilling campaigns at two strategically important projects in Argentina and Austria, setting the stage for assay results that will guide exploration in 2026.

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Prospech Limited advances its Korsnäs rare earth project by transitioning from flotation upgrades to a targeted hydrometallurgical program with ANSTO Minerals, aiming to unlock value from a significant historical concentrate stockpile in Finland.

Proteomics International has secured a US patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma, marking a critical step toward commercialisation in the world’s largest healthcare market.

Liberty Metals has exercised its option to acquire full ownership of a strategically significant portfolio of Brazilian critical minerals projects, positioning itself firmly in the global supply chain for titanium and rare earth elements.

Talga Group launches a $5 million Share Purchase Plan at a discounted price of $0.41 per share, offering eligible shareholders free attaching options as it advances its battery anode production expansion.

ECS Botanics is strategically preparing for entry into the US medicinal cannabis market, leveraging its EU-GMP certification and proprietary genetics amid evolving regulatory landscapes.

Yugo Metals Limited has secured a dual listing on Germany’s Frankfurt and Dusseldorf Stock Exchanges, enhancing its access to European investors, while initial drilling at its Sinjakovo Project in Bosnia-Herzegovina reveals encouraging silver-lead-zinc mineralisation.

Medallion Metals has raised $60 million through a placement and share purchase plan to advance its integrated gold-copper development strategy, targeting first production in early 2027.

Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.

Cynata Therapeutics has finalised patient enrolment in its pivotal Phase 2 trial of CYP-001 for acute graft versus host disease, setting the stage for critical data due mid-2026.

Dimerix has successfully completed recruitment and dosing of 286 adult patients in its Phase 3 ACTION3 trial evaluating DMX-200 for focal segmental glomerulosclerosis (FSGS), advancing toward regulatory discussions with the FDA.